Gastric Cancer

>

Latest News

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.
Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers

July 14th 2025

Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.

Results from the phase 1a/b trial evaluating ADRX-0405 in various solid tumors, including gastric cancer, are expected to come in late 2025.
FDA Grants Orphan Drug Designation to ADRX-0405 for Gastric Cancer

July 9th 2025

Investigators will present detailed results from the phase 3 FORTITUDE-101 trial at a future medical meeting.
Bemarituzumab Regimen Improves Survival in FGFR2b+ Gastric/GEJ Cancer

July 3rd 2025

Subgroup analyses from the phase 3 CheckMate 649 and KEYNOTE-859 clinical trials showed little OS difference between investigational and chemotherapy arms.
FDA Limits Pembrolizumab/Nivolumab in PD-L1–Low Gastric Cancer Indications

June 22nd 2025

Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.
Frontline Nivolumab Combo Shows Enduring Activity in MSI-H Gastric Cancer

June 10th 2025

Video Interviews
Podcasts

More News